QIAseq Targeted DNA Panels

Developed in partnership with leading human identity labs around the world, QIAseq Investigator panels are designed to pick up where conventional STR/capillary testing cannot resolve a case. There are separate, dedicated panels for common human identify questions like biogeographical ancestry prediction, missing persons identification, or paternity testing. Focus your sequencing and data analysis efforts only on the markers of interest in your own case and increase your chances of success with QIAseq.

The QIAseq HRR Panel has been developed as a complete Sample to Insight solution to expand HRR biomarkers beyond BRCA1 and BRCA2. The panel's digital DNA sequencing is a unique approach to detect low-frequency variants with high confidence by overcoming the issues of PCR duplicates, false positives and library bias. The panel is a one-box, NGS platform-agnostic solution that contains all the necessary components to construct libraries from enriched genomic targets. Primer design is based on single primer extension, in which each genomic target is enriched by one target-specific primer and a universal primer, a strategy that removes conventional two target-specific primer design restriction and reduces the amount of required primers. All primers required for a panel are pooled into an individual primer pool to reduce panel handling and number of pools required for enrichment and library construction. . The unique buffer and enzyme system used in the QIAseq HRR panel has been optimized to achieve high coverage of GC-rich genomic regions. Platform-specific indexes, which are contained in a separate box, allow the multiplexing of up to 384 samples per sequencing run.

Researchers face the challenge of creating a reliable, consistent workflow for easily processing samples to understand the mutational landscape of tumors. Tumor Mutational Burden (TMB) is the measure of the number of mutations found within a tumor. However, a lack of standardized testing has prevented any meaningful movement to create a TMB biomarker. The new QIAseq Tumor Mutational Burden Panels overcome the challenges of earlier assay designs to create a comprehensive profile of TMB and Microsatellite Instability (MSI) status by achieving high analytical sensitivity, with lower false and negative rates, while still maintaining >95% correlation with whole exome datasets. QIAseq NGS assays, including the QIAseq TMB and MSI Panels, have a fail rate of less than 5% for samples that have passed QC and provide a TMB score. The QIAseq TMB Panel has been tested in several key opinion leader labs and has performed as well or better than many earlier products. This comprehensive panel covers 486 genes and can be boosted to add 27 MSI markers.